Clinical Trial Update: A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas [Phase 2]

View source ↗

Summary

Phase 2 trial of tumor-reactive autologous tumor-infiltrating lymphocytes (TIL) in metastatic melanoma has terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Tumor-reactive autologous tumor-infiltrating lymphocytes (TIL) (tumor-infiltrating lymphocytes)

Snippet

Sponsor: Saint John's Cancer Institute | Conditions: Metastatic Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2021-09-22